Get all your news in one place.

100’s of premium titles.
One app.

Start reading

Get all your news in one place.

100’s of premium titles. One news app.

Start reading

The Latest Breaking News from AbbVie

How Far Will AbbVie's Humira Revenue Fall in 2023?

The world's best-selling drug begins losing patent protections next year. AbbVie's revenue could take years to recover.

The Street

Check Out What Whales Are Doing With ABBV

Someone with a lot of money to spend has taken a bearish stance on AbbVie (NYSE:ABBV). And retail traders should know. We noticed this today when the big position showed up on publicly available options history that we track here at Benzinga.

Benzinga

This Is What Whales Are Betting On AbbVie

Benzinga

From analysis to the latest developments in health,
read the most diverse news in one place.

A Longer-Acting Botox Competitor is Coming

Revance Therapeutics claimed FDA approval for Daxxify. Ramping sales will take years.

The Street

What Are Whales Doing With AbbVie

A whale with a lot of money to spend has taken a noticeably bearish stance on AbbVie. Looking at options history for AbbVie (NYSE:ABBV) we detected 16 strange trades.

Benzinga

Looking At AbbVie's Recent Whale Trades

Someone with a lot of money to spend has taken a bullish stance on AbbVie (NYSE:ABBV). And retail traders should know. We noticed this today when the big position showed up on publicly available options history that we track here at Benzinga.

Benzinga

Looking At AbbVie's Recent Whale Trades

A whale with a lot of money to spend has taken a noticeably bullish stance on AbbVie. Looking at options history for AbbVie (NYSE:ABBV) we detected 12 strange trades.

Benzinga

Read news from The Economist, FT, and more,
with one subscription

Looking At AbbVie's Recent Whale Trades

Benzinga

Illinois Senate President Don Harmon, other pols keep taking money from pharma companies implicated in opioid crisis

The Oak Park Democrat continues to accept campaign money from Johnson & Johnson, 1 of 4 companies paying $26 billion to settle suits accusing them of fueling the crisis. He’s not the only Illinois official doing so.

Chicago Sun-Times

4 "Strong Buy" Stocks for a Fear-Driven Market

Even though the inflation declined slightly from the 40-year high in July, it stayed elevated. Therefore, the Fed could maintain its hawkish stance on tightening monetary policy, which will drive market volatility. Amid this fear-driven market, we think it could be prudent to invest in fundamentally sound stocks AbbVie (ABBV),…

StockNews.com

Looking At AbbVie's Recent Whale Trades

A whale with a lot of money to spend has taken a noticeably bearish stance on AbbVie. Looking at options history for AbbVie (NYSE:ABBV) we detected 12 strange trades.

Benzinga

Recession Investing: 5 High Yield Dividend Stocks For A Downturn

As the healthcare industry absorbed enormous amounts of profits during the Covid-19 pandemic, many healthcare companies will be increasing shareholder distributions to entice investors to buy their stock.

Benzinga

3 Stocks to Help You Survive and Thrive in Today's Market

Growing concerns over sky-high inflation, the Fed’s aggressive interest rate hikes, the decline in GDP for two consecutive quarters, and increasing odds of a recession are expected to keep the stock market under tremendous pressure in the near term. Amid this backdrop, investing in fundamentally sound stocks AbbVie (ABBV), Acuity…

StockNews.com

Biotech Daily: Trial Setback For Eliem Therapeutics, Allarity Drops Work On Cancer Monotherapies, Axcella Aces Long COVID Study

Here's a roundup of top developments in the biotech space over the last 24 hours:

Benzinga

Get all your
news in one place.

100’s of premium titles.
One news app.

Benzinga

Recap Of Friday's Biotech Catalysts - End of The Day Summary

The U.S. Food and Drug Administration (FDA) has approved Arcutis Biotherapeutics’ (NASDAQ:ARQT) New Drug Application (NDA) for ZORYVE (roflumilast) cream 0.3% for the treatment of plaque psoriasis in patients 12 years of age or older. The company expects commercial launch of the product in Mid-August. Arcutis shares traded in a range of…

Benzinga

What Are Whales Doing With AbbVie

A whale with a lot of money to spend has taken a noticeably bearish stance on AbbVie. Looking at options history for AbbVie (NYSE:ABBV) we detected 18 strange trades.

Investors Business Daily

AbbVie Leans On Immunology Drugs To Offset Aesthetic Downturn Amid Covid

AbbVie leaned heavily on immunology drugs in the second quarter, helping offset declines for key drugs. But AbbVie stock fell early Friday.

The Conversation

Direct-acting antivirals can cure hepatitis C and prisons are now leading efforts to eliminate the virus

While most medical attention has been on COVID, work has been underway to eliminate another viral disease, hepatitis C.

Get all your
news in one place.

100’s of premium titles.
One news app.

Benzinga

Recap of Wednesday's Biotech Catalysts - End of The Day Summary

IDEAYA Biosciences (NASDAQ:IDYA) has entered into a clinical trial collaboration and supply agreement with Amgen Inc. to evaluate the efficacy and safety of IDE397 with Amgen's AMG 193 in a Phase 1 clinical trial. IDEAYA shares traded in a range of $14.59 to $15.82 on a day volume of 130.58…

Benzinga

Recap Of Tuesday's Biotech Catalysts - End of The Day Summary

European Commission (EC) has approved AbbVie’s (NYSE:ABBV) lead asset RINVOQ (upadacitinib 45 mg [induction dose] and 15 mg and 30 mg [maintenance doses]) for the treatment of adult patients with moderately to severely active ulcerative colitis. AbbVie shares traded in a range of $150.33 to $153.56 on a day volume…

Investors Business Daily

Keep AbbVie Stock On Your Watch List Ahead Of Earnings

AbbVie is within striking distance of a buy zone ahead of its next quarterly earnings report, expected on or around Jul. 29.

Benzinga

Recap of Wednesday's Biotech Catalysts - End of The Day Summary

Benzinga

Recap of Monday's Biotech Catalysts - End of the Day Summary

Abbvie (NYSE: ABBV) has submitted a marketing authorization application (MAA) to the European Medicines Agency (EMA) for atogepant for the prophylaxis of migraine in adult patients who have at least four migraine days per month.

Investors Business Daily

Dow Jones Giant UnitedHealth Breaks Out, Leading 5 Stocks To Watch

Dow Jones stock UnitedHealth and AbbVie boast favorable tailwinds. They lead this week's top stocks to watch.

Benzinga

AbbVie Whale Trades Spotted

A whale with a lot of money to spend has taken a noticeably bearish stance on AbbVie. Looking at options history for AbbVie (NYSE:ABBV) we detected 10 strange trades.

1 … 6 7 8 9

People

Mangeet Kaur BounsMangeet

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Food and Drug Administration

324 stories

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.